RUTW241203C1960000
- 0.00
- 0.000.00%
Russell 2000 Index Newsroom
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $72
Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $16
Decoding 6 Analyst Evaluations For Pacira BioSciences
National Bank of Canada Earnings Review: Q4 Summary
Relay Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $7.5 Price Target
Foot Locker Expects 2024 Sales To Decline Between 1.5% To 1.0%, Compared To Prior Guidance Of -1.0% To +1.0%, With Comparable Sales Growth Of +1.0% To +1.5% Vs. Prior Guidance Of +1.0% To +3.0%
Barclays Maintains Overweight on RadNet, Raises Price Target to $85
Rhythm Pharmaceuticals Analyst Ratings
RadNet Analyst Ratings
Heron Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target
Coherus BioSciences Analyst Ratings
Barclays Maintains Overweight on FTAI Aviation, Raises Price Target to $180
FTAI Aviation Analyst Ratings
Pacira BioSciences Analyst Ratings
Top 3 Health Care Stocks That Could Blast Off In December
Macerich Analyst Ratings
Mizuho Initiates Coverage On LifeMD With Neutral Rating, Announces Price Target of $7